December 2004 in “Annales d Urologie” This article examines the PCPT study on whether daily finasteride can reduce prostate cancer incidence, describing its methodology and findings but reporting no new clinical results.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
August 2003 in “Oncology Times” This article discusses the considerations and challenges surrounding a proposed large-scale trial on testosterone-replacement therapy in older men and reports no new results.
This study found that PRP injections may safely improve penile curvature and PDQ scores in men with stable-phase Peyronie's Disease, although the curvature reduction observed was not enough to determine long-term clinical significance.
7 citations
,
April 2008 in “Progrès en Urologie”
This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.
July 2026 in “British journal of surgery” This study found that a substantial number of patients continued tamsulosin and/or finasteride unnecessarily after prostate surgery, with poor documentation and communication contributing to this issue.
April 2023 in “Medicina Clínica (english Edition)” In this study, a risk score was developed and validated to identify patients at high risk of clinical failure after femoropopliteal peripheral vascular intervention, aiming to guide the selection of patients who may benefit from paclitaxel-coated devices or alternative strategies.
14 citations
,
August 2020 in “Journal of cosmetic dermatology” This consensus report provides detailed recommendations for using Polynucleotides Highly Purified Technology™ in aesthetic skin rejuvenation, highlighting its potential as a biostimulatory booster for face and body revitalization.
March 2005 in “The Nurse Practitioner” This update provides information on new drug approvals but does not offer new clinical research findings.
April 2018 in “The Journal of urology/The journal of urology” This study identified several patient-specific factors that can predict both the likelihood of undergoing and failing a post-TURP void trial, aiding in the selection of candidates for immediate assessment.
April 2017 in “The Journal of Urology” This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.
33 citations
,
May 2017 in “Journal of Clinical Oncology” This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.
January 2026 in “Pakistan journal of urology.” This case study detailed a rare instance of Penile Thread Tourniquet Syndrome in a 10-year-old boy, where a thread caused localized infection and edema without urethral damage, ultimately resulting in a favorable outcome through surgical and conservative management.
May 2024 in “International journal of medicine and psychology.” In this study, combining transcranial electrical stimulation with bisphosphonate therapy in patients with postmenopausal osteoporosis resulted in a protective effect on bone collagen synthesis, as indicated by higher P1NP levels over 12 months, compared to bisphosphonates alone.
January 2026 in “Andrology” This study found that PRP injections are safe and may slightly reduce penile curvature and improve PDQ scores in men with stable-phase Peyronie's Disease, but the changes are not significant enough to predict long-term effects.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
14 citations
,
January 2022 in “Evidence-based Complementary and Alternative Medicine” This study found that cryptotanshinone improved bone mass, inhibited osteoclast differentiation, and protected against kidney damage in ovariectomized rats, suggesting potential benefits for clinical use.
14 citations
,
February 2014 in “Nutrition in Clinical Practice” This A.S.P.E.N. document offers guidance for managing parenteral nutrition shortages, emphasizing alternative routes and careful allocation to prevent deficiencies.
This study found that a short-term treatment with all-trans retinoic acid may effectively stabilize platelet counts in idiopathic thrombocytopenic purpura patients experiencing fluctuations during thrombopoietin receptor agonist therapy.
1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
6 citations
,
March 2005 in “The Journal of Urology” This study evaluates finasteride's safety and efficacy for treating male chronic pelvic pain syndrome, but the abstract does not report any results.
13 citations
,
February 2024 in “Clinical Cosmetic and Investigational Dermatology” This study demonstrated that intradermal treatment with a medical device using Polynucleotides High Purification Technology (PN HPT) significantly improved skin surface, firmness, pigmentation, and radiance in 30 Asian subjects, with benefits lasting up to six months and no adverse events reported.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
1 citations
,
August 2021 in “Preventive Medicine” This study found that non-adherence to medication in the Prostate Cancer Prevention Trial was associated with increased all-cause mortality unrelated to prostate cancer.
1 citations
,
April 2022 in “The Journal of Urology” This study observed that discontinuation rates due to side effects were similar for penicillamine and tiopronin among cystinuria patients, and switching to the alternative agent was beneficial for half of those experiencing issues.
March 2022 in “Oncology Times” In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.
80 citations
,
April 2017 in “Frontiers in Pharmacology” This review examines experimental and clinical evidence on PDRN, a drug derived from salmon DNA that acts via the adenosine A2A receptor and shows promise for tissue repair and treatment of diabetic foot ulcers in regenerative medicine.